

Magnus Ingelman-Sundberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5867950/publications.pdf>

Version: 2024-02-01

367
papers

28,387
citations

3731

89
h-index

9589

142
g-index

392
all docs

392
docs citations

392
times ranked

21107
citing authors

#	ARTICLE	IF	CITATIONS
1	3D human liver spheroids for translational pharmacology and toxicology. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 5-15.	2.5	25
2	The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients. Clinical Pharmacology and Therapeutics, 2022, 111, 1165-1174.	4.7	12
3	Dynamics of Metabolic Pathways and Stress Response Patterns during Human Neural Stem Cell Proliferation and Differentiation. Cells, 2022, 11, 1388.	4.1	2
4	Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids. Cells, 2022, 11, 1597.	4.1	0
5	The missing heritability in pharmacogenomics: role of NFIB and other factors. Pharmacogenomics, 2022, 23, 453-455.	1.3	1
6	Cytochrome P450 polymorphism: From evolution to clinical use. Advances in Pharmacology, 2022, , .	2.0	2
7	The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals. Pharmacogenomics Journal, 2022, 22, 247-249.	2.0	7
8	Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism. Archives of Toxicology, 2021, 95, 11-25.	4.2	10
9	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure. JAMA Psychiatry, 2021, 78, 270.	11.0	91
10	Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders. Schizophrenia Research, 2021, 228, 590-596.	2.0	12
11	A Novel CYP2CâHaplotype Associated With Ultrarapid Metabolism of Escitalopram. Clinical Pharmacology and Therapeutics, 2021, 110, 786-793.	4.7	28
12	Evaluation of the <i>CYP2D6</i> Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. Clinical Pharmacology and Therapeutics, 2021, 110, 750-758.	4.7	22
13	Primary human hepatocyte spheroids as an <i>in vitro</i> tool for investigating drug compounds with low clearance. Drug Metabolism and Disposition, 2021, , DMD-AR-2020-000340.	3.3	22
14	CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. International Journal of Molecular Sciences, 2021, 22, 8221.	4.1	90
15	Toward predicting CYP2D6-mediated variable drug response from <i>CYP2D6</i> gene sequencing data. Science Translational Medicine, 2021, 13, .	12.4	42
16	Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology, 2020, 45, 570-576.	5.4	33
17	One nonâ€believer: Response to â€Obviously Nine Believers: Actionable Germline Genetic Variants for Preâ€emptive Pharmacogenetic Testingâ€. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 7-8.	2.5	1
18	Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clinical Pharmacology and Therapeutics, 2020, 107, 1240-1255.	4.7	62

#	ARTICLE	IF	CITATIONS
19	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 131-148.	46.4	153
20	Translation of pharmacogenomic drug labels into the clinic. Current problems. <i>Pharmacological Research</i> , 2020, 153, 104620.	7.1	9
21	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , 2020, 11, 575540.	3.5	46
22	A 3D Cell Culture Model Identifies Wnt/ β -Catenin Mediated Inhibition of p53 as a Critical Step during Human Hepatocyte Regeneration. <i>Advanced Science</i> , 2020, 7, 2000248.	11.2	37
23	Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs – A study based on blood sample analyses from 24,239 patients. <i>European Neuropsychopharmacology</i> , 2020, 37, 64-69.	0.7	10
24	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	1.5	26
25	Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein. <i>Chemico-Biological Interactions</i> , 2020, 325, 109131.	4.0	7
26	Can CYP Inhibition Overcome Chemotherapy Resistance?. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 503-506.	8.7	10
27	Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. <i>Npj Genomic Medicine</i> , 2020, 5, 9.	3.8	42
28	Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. <i>Cells</i> , 2020, 9, 964.	4.1	47
29	Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 844-855.	4.7	31
30	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. <i>Frontiers in Psychiatry</i> , 2020, 11, 94.	2.6	74
31	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. <i>Scientific Reports</i> , 2019, 9, 11585.	3.3	82
32	4th ESPT Conference: pharmacogenomics and personalized medicine – research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019, 20, 1063-1069.	1.3	1
33	CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma. <i>Pharmacogenomics</i> , 2019, 20, 1085-1092.	1.3	2
34	Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids. <i>Toxicological Sciences</i> , 2019, 171, 385-395.	3.1	19
35	IMPACT OF CYP GENOTYPE ON THE SUCCESS OF ANTIDEPRESSANT THERAPY. <i>European Neuropsychopharmacology</i> , 2019, 29, S1030.	0.7	0
36	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. , 2019, 197, 122-152.		83

#	ARTICLE	IF	CITATIONS
37	Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 130, 65-77.	4.0	51
38	Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. <i>Lancet Psychiatry</i> , 2019, 6, 418-426.	7.4	113
39	Development of the <sc>PG</sc>â€”Passport: A Panel of Actionable Germline Genetic Variants for Preâ€”emptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 866-873.	4.7	73
40	3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications. <i>Biotechnology Journal</i> , 2019, 14, e1800347.	3.5	97
41	AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 217-226.	7.1	68
42	Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. <i>Archives of Toxicology</i> , 2019, 93, 385-399.	4.2	23
43	Significantly lower CYP2D6 metabolism measured as the <i>O/N</i>â€”desmethylvenlafaxine metabolic ratio in carriers of <i>CYP2D6*41</i> versus <i>CYP2D6*9</i> or <i>CYP2D6*10</i>: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 194-201.	2.4	28
44	Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions. <i>Toxicological Sciences</i> , 2018, 163, 655-665.	3.1	140
45	Impact of <i>CYP2C19</i> Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. <i>American Journal of Psychiatry</i> , 2018, 175, 463-470.	7.2	136
46	Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study. <i>Toxicological Sciences</i> , 2018, 162, 655-666.	3.1	219
47	How to Consider Rare Genetic Variants in Personalized Drug Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 745-748.	4.7	36
48	Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. <i>Genetics in Medicine</i> , 2018, 20, 622-629.	2.4	66
49	Pharmacoepigenetics and Toxicopigenetics: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 161-185.	9.4	45
50	Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 65-82.	9.4	95
51	Pharmacogenomic Biomarkers for Improved Drug Therapyâ€”Recent Progress and Future Developments. <i>AAPS Journal</i> , 2018, 20, 4.	4.4	106
52	Transcriptomic, Proteomic, and Functional Long-Term Characterization of Multicellular Three-Dimensional Human Liver Microtissues. <i>Applied in Vitro Toxicology</i> , 2018, 4, 1-12.	1.1	46
53	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (<i>CYP</i>) Allele Nomenclature Database. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 399-401.	4.7	335
54	Human hepatic 3D spheroids as a model for steatosis and insulin resistance. <i>Scientific Reports</i> , 2018, 8, 14297.	3.3	108

#	ARTICLE	IF	CITATIONS
55	Current Statistical Metrics Are Pragmatic Measures to Compare the Predictive Quality of Preclinical Assays. <i>Toxicological Sciences</i> , 2018, 165, 4-5.	3.1	4
56	Integrating rare genetic variants into pharmacogenetic drug response predictions. <i>Human Genomics</i> , 2018, 12, 26.	2.9	166
57	Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions. <i>Pharmacogenomics</i> , 2018, 19, 1133-1138.	1.3	13
58	Functional characterization of CYP2D7 gene variants. <i>Pharmacogenomics</i> , 2018, 19, 931-936.	1.3	1
59	Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. <i>Tissue Engineering - Part C: Methods</i> , 2018, 24, 534-545.	2.1	69
60	Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent. <i>Toxicology Letters</i> , 2018, 295, 187-194.	0.8	17
61	Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-9-16.	0.0	0
62	Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. <i>Genetics in Medicine</i> , 2017, 19, 20-29.	2.4	194
63	Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury. <i>Drug Metabolism and Disposition</i> , 2017, 45, 419-429.	3.3	141
64	Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. <i>FASEB Journal</i> , 2017, 31, 2696-2708.	0.5	119
65	Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 765-770.	8.7	11
66	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 241-248.	12.0	20
67	The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 399-407.	2.1	25
68	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. <i>Hepatology</i> , 2017, 65, 710-721.	7.3	54
69	A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. <i>Archives of Toxicology</i> , 2017, 91, 1385-1400.	4.2	85
70	High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis. <i>Stem Cells International</i> , 2016, 2016, 1-14.	2.5	30
71	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1714.	4.1	73
72	Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas. <i>PLoS ONE</i> , 2016, 11, e0162379.	2.5	6

#	ARTICLE	IF	CITATIONS
73	Pharmacogenomic or â€œepigenomic biomarkers in drug treatment: Two sides of the same medal?. Clinical Pharmacology and Therapeutics, 2016, 99, 478-480.	4.7	18
74	Membrane topology and search for potential redox partners of colon cancerâ€specific cytochrome P450 2W1. FEBS Letters, 2016, 590, 330-339.	2.8	10
75	Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. Scientific Reports, 2016, 6, 35434.	3.3	118
76	Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Scientific Reports, 2016, 6, 25187.	3.3	502
77	Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression. Nucleic Acids Research, 2016, 44, 6756-6769.	14.5	15
78	Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Chemical Research in Toxicology, 2016, 29, 1936-1955.	3.3	196
79	Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology, 2016, 64, 1743-1756.	7.3	100
80	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Archives of Toxicology, 2016, 90, 2979-3003.	4.2	50
81	Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics, 2016, 17, 917-924.	1.3	40
82	The CYP2W1 enzyme: regulation, properties and activation of prodrugs. Drug Metabolism Reviews, 2016, 48, 369-378.	3.6	15
83	Precision Medicine and Rare Genetic Variants. Trends in Pharmacological Sciences, 2016, 37, 85-86.	8.7	52
84	What do animal experiments tell us that inÂvitro systems cannot? The Human Toxome Project. Regulatory Toxicology and Pharmacology, 2016, 75, 1-4.	2.7	3
85	Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells. Stem Cells, 2015, 33, 2936-2948.	3.2	11
86	Genetic variation in the human cytochrome P450 supergene family. Pharmacogenetics and Genomics, 2015, 25, 584-594.	1.5	127
87	Developmental Regulation and Induction of Cytochrome P450 2W1, an Enzyme Expressed in Colon Tumors. PLoS ONE, 2015, 10, e0122820.	2.5	18
88	Expression and Function of mARC: Roles in Lipogenesis and Metabolic Activation of Ximelagatran. PLoS ONE, 2015, 10, e0138487.	2.5	25
89	Stem Cell-Derived Systems in Toxicology Assessment. Stem Cells and Development, 2015, 24, 1284-1296.	2.1	49
90	Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. Toxicological Sciences, 2015, 147, 412-424.	3.1	73

#	ARTICLE	IF	CITATIONS
91	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of <i>In Vitro</i> Models. <i>Applied in Vitro Toxicology</i> , 2015, 1, 175-186.	1.1	5
92	Role of cytochrome P450 <i>CYP2C8</i> in paclitaxel metabolism and paclitaxel-induced neurotoxicity. <i>Pharmacogenomics</i> , 2015, 16, 929-937.	1.3	17
93	Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. <i>Free Radical Biology and Medicine</i> , 2015, 78, 202-212.	2.9	161
94	Whole-Exome Sequencing Reveals Defective <i>CYP3A4</i> Variants Predictive of Paclitaxel Dose-Limiting Neuropathy. <i>Clinical Cancer Research</i> , 2015, 21, 322-328.	7.0	61
95	Personalized medicine into the next generation. <i>Journal of Internal Medicine</i> , 2015, 277, 152-154.	6.0	14
96	Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. <i>Pharmacogenomics</i> , 2014, 15, 1841-1844.	1.3	29
97	Genetic and epigenetic regulation of gene expression in fetal and adult human livers. <i>BMC Genomics</i> , 2014, 15, 860.	2.8	124
98	The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases. <i>Acta Oncologica</i> , 2014, 53, 885-891.	1.8	16
99	Targeted profiling of 5-(hydroxy)methylcytosine in genomic DNA from human livers: Next-generation sequencing of target enriched DNA reveals unexpectedly high interindividual variability of cytosine methylation and hydroxymethylation. , 2014, , .		0
100	Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell-Derived Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1401-1406.	3.3	87
101	High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique Distribution of <i>CYP2A6</i> Variant Alleles in Ethiopian Population. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 446-453.	2.0	23
102	Epigenetic mechanisms of importance for drug treatment. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 384-396.	8.7	129
103	Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6273-6277.	6.4	35
104	<i>CYP2W1</i> polymorphism: functional aspects and relation to risk for colorectal cancer. <i>Pharmacogenomics</i> , 2013, 14, 1615-1622.	1.3	9
105	3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies. <i>Toxicological Sciences</i> , 2013, 133, 67-78.	3.1	197
106	Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. <i>Genome Biology</i> , 2013, 14, R83.	9.6	61
107	Induced CYP3A4 Expression in Confluent Huh7 Hepatoma Cells as a Result of Decreased Cell Proliferation and Subsequent Pregnane X Receptor Activation. <i>Molecular Pharmacology</i> , 2013, 83, 659-670.	2.3	34
108	Potential Role of Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1725-1731.	3.3	68

#	ARTICLE	IF	CITATIONS
109	Strong effects of environmental factors on prevalence and course of major depressive disorder are not moderated by 5-HTTLPR polymorphisms in a large Dutch sample. <i>Journal of Affective Disorders</i> , 2013, 146, 91-99.	4.1	26
110	Characterization of Human Cytochrome P450s Involved in the Bioactivation of Clozapine. <i>Drug Metabolism and Disposition</i> , 2013, 41, 651-658.	3.3	54
111	Update on Allele Nomenclature for Human Cytochromes P450 and the Human Cytochrome P450 Allele (CYP-Allele) Nomenclature Database. <i>Methods in Molecular Biology</i> , 2013, 987, 251-259.	0.9	78
112	An Integrated <i>in Vitro</i> Model for Simultaneous Assessment of Drug Uptake, Metabolism, and Efflux. <i>Molecular Pharmaceutics</i> , 2013, 10, 3152-3163.	4.6	14
113	Hepatic Differentiation and Maturation of Human Embryonic Stem Cells Cultured in a Perfused Three-Dimensional Bioreactor. <i>Stem Cells and Development</i> , 2013, 22, 581-594.	2.1	56
114	Colon Cancer-Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins. <i>Clinical Cancer Research</i> , 2013, 19, 2952-2961.	7.0	47
115	In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. <i>Nucleic Acids Research</i> , 2013, 41, e72-e72.	14.5	43
116	Sex Difference in Formation of Propofol Metabolites: A Replication Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 126-131.	2.5	44
117	Amidoxime Reductase System Containing Cytochrome b5 Type B (CYB5B) and MOSC2 Is of Importance for Lipid Synthesis in Adipocyte Mitochondria. <i>Journal of Biological Chemistry</i> , 2012, 287, 6307-6317.	3.4	52
118	Institutional Profile: Karolinska Institutet. <i>Pharmacogenomics</i> , 2012, 13, 1887-1891.	1.3	2
119	CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. <i>Journal of Psychopharmacology</i> , 2012, 26, 398-407.	4.0	69
120	Epigenomics and Interindividual Differences in Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 727-736.	4.7	114
121	DNA methylation dynamics in the hepatic CYP3A4 gene promoter. <i>Biochimie</i> , 2012, 94, 2338-2344.	2.6	54
122	Epigenetic-dependent regulation of drug transport and metabolism: an update. <i>Pharmacogenomics</i> , 2012, 13, 1373-1385.	1.3	42
123	Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 407-413.	1.9	7
124	Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 397-406.	1.9	69
125	The expression of CYP2W1: a prognostic marker in colon cancer. <i>Anticancer Research</i> , 2012, 32, 3869-74.	1.1	32
126	Pharmacogenomic biomarkers: new tools in current and future drug therapy. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 72-81.	8.7	91

#	ARTICLE	IF	CITATIONS
127	Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using <i>In Vitro</i> Models Derived from Human Embryonic Stem Cells and Human Cell Lines – A Report on the Vitrocellomics EU-project. ATLA Alternatives To Laboratory Animals, 2011, 39, 147-171.	1.0	38
128	Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions. Clinical Pharmacology and Therapeutics, 2011, 89, 902-907.	4.7	63
129	Databases in the area of pharmacogenetics. Human Mutation, 2011, 32, 526-531.	2.5	52
130	The Ligands of Estrogen Receptor ± Regulate Cytochrome P4502C9 (CYP2C9) Expression. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 302-309.	2.5	19
131	Human Embryonic Stem Cell Derived Hepatocyte-Like Cells as a Tool for In Vitro Hazard Assessment of Chemical Carcinogenicity. Toxicological Sciences, 2011, 124, 278-290.	3.1	66
132	Genetic Polymorphism and Toxicology – With Emphasis on Cytochrome P450. Toxicological Sciences, 2011, 120, 1-13.	3.1	213
133	Intronic polymorphisms of cytochromes P450. Human Genomics, 2010, 4, 402.	2.9	22
134	CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. European Journal of Clinical Pharmacology, 2010, 66, 871-877.	1.9	53
135	Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. European Journal of Clinical Pharmacology, 2010, 66, 1199-1205.	1.9	75
136	Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Human Genetics, 2010, 127, 1-17.	3.8	110
137	IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. Biochemical Pharmacology, 2010, 80, 1592-1600.	4.4	22
138	Association between CYP2C19 polymorphism and depressive symptoms. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1160-1166.	1.7	35
139	Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. Journal of Biotechnology, 2010, 145, 284-294.	3.8	105
140	CYP3A4 Catalytic Activity Is Induced in Confluent Huh7 Hepatoma Cells. Drug Metabolism and Disposition, 2010, 38, 995-1002.	3.3	50
141	New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4. Drug Metabolism and Disposition, 2010, 38, 415-421.	3.3	25
142	Regulation of CYP2C19 Expression by Estrogen Receptor ±: Implications for Estrogen-Dependent Inhibition of Drug Metabolism. Molecular Pharmacology, 2010, 78, 886-894.	2.3	53
143	Colorectal Cancer-Specific Cytochrome P450 2W1: Intracellular Localization, Glycosylation, and Catalytic Activity. Molecular Pharmacology, 2010, 78, 1004-1011.	2.3	36
144	Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: Possible role for molecular mimicry. Journal of Hepatology, 2010, 53, 431-438.	3.7	16

#	ARTICLE	IF	CITATIONS
145	The transcription factor GATA-4 regulates cytochrome P450C19 gene expression. Life Sciences, 2010, 86, 699-706.	4.3	24
146	Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochemical and Biophysical Research Communications, 2010, 396, 90-94.	2.1	63
147	Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1075-1084.	4.8	9
148	The past, present and future of pharmacoepigenomics. Pharmacogenomics, 2010, 11, 625-627.	1.3	57
149	Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. Current Opinion in Drug Discovery & Development, 2010, 13, 78-85.	1.9	23
150	Pharmacoepigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response. Expert Review of Clinical Pharmacology, 2009, 2, 55-65.	3.1	4
151	Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function. Drug Metabolism and Disposition, 2009, 37, 1528-1538.	3.3	148
152	Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone. Drug Metabolism and Disposition, 2009, 37, 1505-1512.	3.3	22
153	In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: beyond the reduction of animal model use. Drug Discovery Today, 2009, 14, 401-405.	6.4	14
154	Pharmacoepigenetics: Its Role in Interindividual Differences in Drug Response. Clinical Pharmacology and Therapeutics, 2009, 85, 426-430.	4.7	105
155	The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer â€” A pilot study. European Journal of Cancer, 2009, 45, 705-712.	2.8	42
156	Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicology in Vitro, 2009, 23, 1387-1395.	2.4	37
157	The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. Journal of Hepatology, 2009, 50, 572-583.	3.7	94
158	Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics, 2009, 10, 1067-1076.	1.3	50
159	Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics Journal, 2009, 9, 208-217.	2.0	53
160	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenetics and Genomics, 2009, 19, 565-566.	1.5	30
161	Intracellular transport and localization of microsomal cytochrome P450. Analytical and Bioanalytical Chemistry, 2008, 392, 1075-1084.	3.7	50
162	Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. European Journal of Clinical Pharmacology, 2008, 64, 1175-1179.	1.9	60

#	ARTICLE	IF	CITATIONS
163	Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. Human Mutation, 2008, 29, 1147-1153.	2.5	62
164	Increased omeprazole metabolism in carriers of the <i>CYP2C19*17</i> allele; a pharmacokinetic study in healthy volunteers. British Journal of Clinical Pharmacology, 2008, 65, 767-774.	2.4	129
165	Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions. New England Journal of Medicine, 2008, 358, 637-639.	27.0	125
166	Pro-inflammatory response and adverse drug reactions: Mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. Toxicology in Vitro, 2008, 22, 1588-1594.	2.4	12
167	Cytokine and Chemokine Expression Associated with Steatohepatitis and Hepatocyte Proliferation in Rats Fed Ethanol via Total Enteral Nutrition. Experimental Biology and Medicine, 2008, 233, 344-355.	2.4	59
168	Generation of Mice Transgenic for Human <i>CYP2C18</i> and <i>CYP2C19</i>: Characterization of the Sexually Dimorphic Gene and Enzyme Expression. Drug Metabolism and Disposition, 2008, 36, 955-962.	3.3	45
169	CYP1A1, GSTM1, and GSTT1 Polymorphisms, Smoking, and Lung Cancer Risk in a Pooled Analysis among Asian Populations. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1120-1126.	2.5	54
170	Characterization of the Novel Defective CYP2C9*24 Allele. Drug Metabolism and Disposition, 2007, 35, 831-834.	3.3	6
171	Calcium-regulating peptide hormones and blood electrolytic balance in chronic heart failure. Regulatory Peptides, 2007, 142, 95-100.	1.9	16
172	Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics, 2007, 8, 1315-1325.	1.3	63
173	Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. Glia, 2007, 55, 328-340.	4.9	58
174	Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochemical Pharmacology, 2007, 74, 496-503.	4.4	92
175	Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, 116, 496-526.		990
176	Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. European Journal of Clinical Pharmacology, 2007, 63, 537-546.	1.9	222
177	3'â€²-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochemical and Biophysical Research Communications, 2006, 340, 491-497.	2.1	84
178	Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochemical and Biophysical Research Communications, 2006, 341, 451-458.	2.1	98
179	Metabolism: A Bottleneck in <i>In Vitro</i> Toxicological Test Development. ATLA Alternatives To Laboratory Animals, 2006, 34, 49-84.	1.0	161
180	Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenetics and Genomics, 2006, 16, 191-198.	1.5	145

#	ARTICLE	IF	CITATIONS
181	Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 359-367.	1.5	81
182	A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 103-113.	4.7	620
183	Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 339-349.	4.7	98
184	Pharmacogenomics and Individualized Drug Therapy. <i>Annual Review of Medicine</i> , 2006, 57, 119-137.	12.2	576
185	CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 625-631.	1.5	87
186	Identification and phenotype characterization of two haplotypes causing different enzymatic capacity in fetal livers. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 259-270.	4.7	52
187	Activation of c-fos by lipopolysaccharide in glial cells via p38 mitogen-activated protein kinase-dependent activation of serum or cyclic AMP/calcium response element. <i>Journal of Neurochemistry</i> , 2005, 92, 915-924.	3.9	16
188	Modulation of Oxidative Stress by Alcohol. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 1060-1065.	2.4	5
189	Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. <i>Cellular Signalling</i> , 2005, 17, 39-48.	3.6	96
190	Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. <i>Free Radical Biology and Medicine</i> , 2005, 39, 619-630.	2.9	96
191	Novel extrahepatic cytochrome P450s. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 57-61.	2.8	93
192	The human genome project and novel aspects of cytochrome 450 research. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 52-56.	2.8	111
193	Transcriptional Regulation of the Human CYP2A6 Gene. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 814-822.	2.5	44
194	CHARACTERIZATION AND PARTIAL PURIFICATION OF THE RAT AND HUMAN ENZYME SYSTEMS ACTIVE IN THE REDUCTION OF N-HYDROXYMELAGATRAN AND BENZAMIDOXIME. <i>Drug Metabolism and Disposition</i> , 2005, 33, 570-578.	3.3	35
195	Characterization of Common CYP1B1 Variants with Different Capacity for Benzo[a]pyrene-7,8-Dihydrodiol Epoxide Formation from Benzo[a]pyrene. <i>Cancer Research</i> , 2005, 65, 5105-5111.	0.9	47
196	A Novel Polymorphic Cytochrome P450 Formed by Splicing of CYP3A7 and the Pseudogene CYP3AP1. <i>Journal of Biological Chemistry</i> , 2005, 280, 28324-28331.	3.4	22
197	Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. <i>Atherosclerosis</i> , 2005, 182, 37-45.	0.8	20
198	Phenotypeâ€“genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 299-305.	2.1	93

#	ARTICLE	IF	CITATIONS
199	Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 1065-1074.	2.1	38
200	Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. <i>Toxicology in Vitro</i> , 2005, 19, 621-629.	2.4	52
201	Different Structural Requirements of the Ligand Binding Domain of the Aryl Hydrocarbon Receptor for High- and Low-Affinity Ligand Binding and Receptor Activation. <i>Molecular Pharmacology</i> , 2004, 65, 416-425.	2.3	69
202	Use of Molecular Simulation for Mapping Conformational CYP2E1 Epitopes. <i>Journal of Biological Chemistry</i> , 2004, 279, 50949-50955.	3.4	17
203	Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling. <i>Biochemical Pharmacology</i> , 2004, 67, 1249-1258.	4.4	23
204	Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. <i>Biochemical Pharmacology</i> , 2004, 67, 1389-1397.	4.4	77
205	Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 369, 89-104.	3.0	288
206	A nicotineC-oxidase gene (CYP2A6) polymorphism important for promoter activity. <i>Human Mutation</i> , 2004, 23, 258-266.	2.5	32
207	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. <i>International Journal of Cancer</i> , 2004, 110, 266-270.	5.1	21
208	Characterization and tissue distribution of a novel human cytochrome P450â€”CYP2U1. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 679-685.	2.1	55
209	Lack of sexual dimorphism in alcohol-induced liver damage (ALD) in rats treated chronically with ethanol-containing low carbohydrate diets: The role of ethanol metabolism and endotoxin. <i>Life Sciences</i> , 2004, 75, 469-483.	4.3	16
210	Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 193-200.	8.7	579
211	Dietary long-chain nâ”3 fatty acids for the prevention of cancer: a review of potential mechanisms. <i>American Journal of Clinical Nutrition</i> , 2004, 79, 935-945.	4.7	813
212	Alcoholic Liver Disease in Rats Fed Ethanol as Part of Oral or Intragastric Low-Carbohydrate Liquid Diets. <i>Experimental Biology and Medicine</i> , 2004, 229, 351-360.	2.4	35
213	Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). <i>Cancer Causes and Control</i> , 2003, 14, 339-346.	1.8	98
214	Xanthine oxidase activity is influenced by environmental factors in Ethiopians. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 533-536.	1.9	28
215	CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls. <i>International Journal of Cancer</i> , 2003, 104, 650-657.	5.1	140
216	COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM. <i>Drug Metabolism and Disposition</i> , 2003, 31, 755-761.	3.3	213

#	ARTICLE	IF	CITATIONS
217	COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1093-1102.	3.3	77
218	Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. <i>Carcinogenesis</i> , 2003, 24, 681-687.	2.8	44
219	CYKI-47261, A NEW AMPA [2-AMINO-3-(3-HYDROXYMETHYLISOXAZOLE-4-YL)PROPIONIC ACID] ANTAGONIST, IS A CYP2E1 INDUCER. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1310-1314.	3.3	6
220	Mechanisms of Down-Regulation of CYP2E1 Expression by Inflammatory Cytokines in Rat Hepatoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 1048-1054.	2.5	68
221	Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. <i>Carcinogenesis</i> , 2003, 24, 1533-1539.	2.8	69
222	Genetic Polymorphism of CYP1A2 in Ethiopians Affecting Induction and Expression: Characterization of Novel Haplotypes with Single-Nucleotide Polymorphisms in Intron 1. <i>Molecular Pharmacology</i> , 2003, 64, 659-669.	2.3	158
223	Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. <i>Biomarkers</i> , 2002, 7, 230-241.	1.9	68
224	Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. <i>Carcinogenesis</i> , 2002, 23, 1343-1350.	2.8	250
225	Functional Analysis of Six Different Polymorphic CYP1B1 Enzyme Variants Found in an Ethiopian Population. <i>Molecular Pharmacology</i> , 2002, 61, 586-594.	2.3	120
226	Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 375-383.	5.7	81
227	Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a role for glutathione and GRP94 in the heme- ϵ -protein assembly. <i>Archives of Biochemistry and Biophysics</i> , 2002, 408, 58-68.	3.0	11
228	Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. <i>Human Mutation</i> , 2002, 20, 275-283.	2.5	94
229	The neuroprotective agents chlomethiazole and SB203580 inhibit IL-1 β signalling but not its biosynthesis in rat cortical glial cells. <i>Journal of Neurochemistry</i> , 2002, 83, 727-737.	3.9	20
230	Polymorphism of cytochrome P450 and xenobiotic toxicity. <i>Toxicology</i> , 2002, 181-182, 447-452.	4.2	92
231	The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 77-88.	4.7	73
232	Genetic variability in susceptibility and response to toxicants. <i>Toxicology Letters</i> , 2001, 120, 259-268.	0.8	63
233	Identification and Tissue Distribution of the Novel Human Cytochrome P450 2S1 (CYP2S1). <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 529-535.	2.1	105
234	Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 1349-1355.	2.1	167

#	ARTICLE	IF	CITATIONS
235	Identification of a Single Nucleotide Polymorphism in the TATA Box of the CYP2A6 Gene: Impairment of Its Promoter Activity. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 455-460.	2.1	144
236	The Importance of Residues in Substrate Recognition Site 3 for the Catalytic Function of CYP2D25 (Vitamin D 25-Hydroxylase). <i>Biochemical and Biophysical Research Communications</i> , 2001, 288, 1059-1063.	2.1	13
237	Genetic and environmental causes for interindividual variability in drug pharmacokinetics. <i>International Congress Series</i> , 2001, 1220, 175-186.	0.2	2
238	Integration of In Vitro Approaches to Predict Drug Metabolism and Interaction in Man: An EU Validation Project. <i>ATLA Alternatives To Laboratory Animals</i> , 2001, 29, 305-306.	1.0	2
239	Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 417-427.	5.7	77
240	Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 447-450.	2.4	186
241	The Ubiquitin-Proteasome 26s Pathway in Liver Cell Protein Turnover: Effect of Ethanol and Drugs. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 225S-229S.	2.4	23
242	Ethanol and Oxidative Stress. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 237S-243S.	2.4	93
243	Identification and Characterization of a Mitochondrial Targeting Signal in Rat Cytochrome P450 2E1 (CYP2E1). <i>Journal of Biological Chemistry</i> , 2001, 276, 11317-11322.	3.4	43
244	The Ubiquitin-Proteasome 26s Pathway in Liver Cell Protein Turnover: Effect of Ethanol and Drugs. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 225S-229S.	2.4	11
245	Ethanol and Oxidative Stress. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 237S-243S.	2.4	48
246	Neuroprotective Agent Chlormethiazole Attenuates c-fos, c-jun, and AP-1 Activation through Inhibition of p38 MAP Kinase. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 1077-1088.	4.3	44
247	Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa. <i>Biochemical Pharmacology</i> , 2000, 59, 1425-1432.	4.4	34
248	Molecular Basis for the Transport of Cytochrome P450 2E1 to the Plasma Membrane. <i>Journal of Biological Chemistry</i> , 2000, 275, 17130-17135.	3.4	61
249	Identification of CYP4F8 in Human Seminal Vesicles as a Prominent 19-Hydroxylase of Prostaglandin Endoperoxides. <i>Journal of Biological Chemistry</i> , 2000, 275, 21844-21849.	3.4	72
250	Characterization and Functional Analysis of Two Common Human Cytochrome P450 1B1 Variants. <i>Archives of Biochemistry and Biophysics</i> , 2000, 378, 175-181.	3.0	52
251	Cyclic Expression of Class I Alcohol Dehydrogenase in Male Rats Treated with Ethanol. <i>Biochemical and Biophysical Research Communications</i> , 2000, 274, 684-688.	2.1	31
252	The Effect of Ethanol-Induced Cytochrome p4502E1 on the Inhibition of Proteasome Activity by Alcohol. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 23-29.	2.1	112

#	ARTICLE	IF	CITATIONS
253	Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. <i>Journal of Hepatology</i> , 2000, 32, 900-910.	3.7	66
254	Autoantibodies against Cytochromes P-4502E1 and P-4503A in Alcoholics. <i>Molecular Pharmacology</i> , 1999, 55, 223-233.	2.3	66
255	Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. <i>Archives of Toxicology</i> , 1999, 73, 33-40.	4.2	47
256	Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells. <i>FEBS Journal</i> , 1999, 261, 66-71.	0.2	37
257	Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. <i>Hepatology</i> , 1999, 29, 1503-1510.	7.3	112
258	Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. , 1999, 81, 325-329.		86
259	Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. <i>Trends in Pharmacological Sciences</i> , 1999, 20, 342-349.	8.7	470
260	Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. <i>Gene</i> , 1999, 226, 327-338.	2.2	141
261	Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. <i>FEBS Letters</i> , 1999, 448, 105-110.	2.8	182
262	A soluble NH2-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria. <i>FEBS Letters</i> , 1999, 460, 309-314.	2.8	53
263	Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. <i>FEBS Letters</i> , 1999, 460, 321-327.	2.8	158
264	GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUES. <i>Drug Metabolism Reviews</i> , 1999, 31, 467-487.	3.6	92
265	Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish Population. <i>Biochemical and Biophysical Research Communications</i> , 1999, 254, 628-631.	2.1	239
266	Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5'-Upstream Regulatory Region. <i>Biochemical and Biophysical Research Communications</i> , 1999, 259, 201-205.	2.1	280
267	Structural and Functional Characterization of the 5'-Flanking Region of the Rat and Human Cytochrome P450 2E1 Genes: Identification of a Polymorphic Repeat in the Human Gene. <i>Biochemical and Biophysical Research Communications</i> , 1999, 263, 286-293.	2.1	85
268	Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. <i>Biochemical Journal</i> , 1999, 340, 453-458.	3.7	63
269	ROLE OF CYTOCHROME P450 ENZYMES IN ALCOHOL LIVER DISEASE PATHOGENESIS. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 739-740.	2.4	3
270	CYTOCHROME P4502E1, HYDROXYETHYL FREE RADICALS, AND IMMUNE REACTIONS ASSOCIATED WITH ALCOHOLIC LIVER DISEASE. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 740-742.	2.4	8

#	ARTICLE	IF	CITATIONS
271	A stress-inducible rat liver endoplasmic reticulum protein, ERp29. FEBS Journal, 1998, 251, 304-313.	0.2	85
272	Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 1998, 27, 128-133.	7.3	573
273	Zonated expression of cytokines in rat liver: Effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole. Hepatology, 1998, 27, 1304-1310.	7.3	86
274	Oligomerization properties of ERp29, an endoplasmic reticulum stress protein. FEBS Letters, 1998, 431, 322-326.	2.8	37
275	Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C -oxidase. FEBS Letters, 1998, 438, 201-205.	2.8	129
276	Expression and Distribution of Cytochrome P450 Enzymes in Male Rat Kidney: Effects of Ethanol, Acetone and Dietary Conditions. Biochemical Pharmacology, 1998, 55, 123-129.	4.4	59
277	Signal Transduction-mediated Activation of the Aryl Hydrocarbon Receptor in Rat Hepatoma H4IIE Cells. Journal of Biological Chemistry, 1997, 272, 31755-31763.	3.4	106
278	Lipid Peroxidation, CYP2E1 and Arachidonic Acid Metabolism in Alcoholic Liver Disease in Rats. Journal of Nutrition, 1997, 127, 907S-911S.	2.9	87
279	Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics and Genomics, 1997, 7, 187-191.	5.7	201
280	Pretranslational and Posttranslational Regulation of Rat Hepatic CYPs 3A2 and 2E1 by Disulfiram. Biochemical Pharmacology, 1997, 54, 1323-1329.	4.4	15
281	Detection of Cytochrome P4503A (CYP3A) in Human Hepatic Stellate Cells. Biochemical and Biophysical Research Communications, 1997, 238, 420-424.	2.1	18
282	Characterization of a Human Glutathione S-Transferase $\frac{1}{4}$ Cluster Containing a Duplicated GSTM1 Gene that Causes Ultrarapid Enzyme Activity. Molecular Pharmacology, 1997, 52, 958-965.	2.3	112
283	A Combination of Mutations in the CYP2D6*17 (CYP2D6Z) Allele Causes Alterations in Enzyme Function. Molecular Pharmacology, 1997, 52, 1034-1040.	2.3	134
284	Selective Fast Degradation of Cytochrome P-450 2E1 in Serum-Deprived Hepatoma Cells by a Mechanism Sensitive to Inhibitors of Vesicular Transport. FEBS Journal, 1997, 247, 37-43.	0.2	15
285	Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats. Biochemical Pharmacology, 1996, 51, 61-69.	4.4	46
286	Enzyme-Specific Transport of Rat Liver Cytochrome P450 to the Golgi Apparatus. Archives of Biochemistry and Biophysics, 1996, 333, 459-465.	3.0	52
287	High Rates of Substrate Hydroxylation by Human Cytochrome P450 3A4 in Reconstituted Membranous Vesicles: Influence of Membrane Charge. Biochemical and Biophysical Research Communications, 1996, 221, 318-322.	2.1	50
288	Hepatotoxicity induced by iron overload and alcohol. Journal of Hepatology, 1996, 25, 538-546.	3.7	52

#	ARTICLE	IF	CITATIONS
289	Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 441-447.	5.7	98
290	PCR-based genotyping for duplicated and deleted CYP2D6 genes. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 351-355.	5.7	103
291	The role of CYP2E1 and 2B1 in metabolic activation of benzene derivatives. <i>Archives of Toxicology</i> , 1996, 71, 45-56.	4.2	54
292	A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 713-719.	2.4	189
293	[24] Genetic polymorphism of human cytochrome P450 2E1. <i>Methods in Enzymology</i> , 1996, 272, 218-225.	1.0	17
294	Expression, Catalytic Activity, and Inducibility of Cytochrome P450 2E1 (CYP2E1) in the Rat Central Nervous System. <i>Journal of Neurochemistry</i> , 1996, 67, 2066-2073.	3.9	55
295	Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 656-661.	4.7	86
296	Effect of carrageenan-induced granuloma on hepatic cytochrome P-450 isozymes in rats. <i>Inflammation</i> , 1995, 19, 143-156.	3.8	12
297	Induction mechanisms of cytochrome P450 2E1 in liver: Interplay between ethanol treatment and starvation. <i>Biochemical Pharmacology</i> , 1995, 50, 155-161.	4.4	59
298	Inhibition of CYP2E1 Activity does not Abolish Pulsatile Urine Alcohol Concentrations During Chronic Alcohol Infusions. <i>FEBS Journal</i> , 1995, 230, 914-919.	0.2	0
299	Inhibition of CYP2E1 Activity does not Abolish Pulsatile Urine Alcohol Concentrations During Chronic Alcohol Infusions. <i>FEBS Journal</i> , 1995, 230, 914-919.	0.2	17
300	Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. <i>Biochemical Pharmacology</i> , 1994, 48, 1823-1833.	4.4	45
301	Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail (<i>Colinus virginianus</i>) by ergosterol biosynthesis inhibiting fungicides (EBIFs). <i>Biochemical Pharmacology</i> , 1994, 48, 1953-1965.	4.4	105
302	[11] Spin trapping of alcohol-derived radicals in microsomes and reconstituted systems by electron spin resonance. <i>Methods in Enzymology</i> , 1994, 233, 117-127.	1.0	23
303	Differential regulation of gelatinase b and tissue-type plasminogen activator expression in human bowes melanoma cells. <i>International Journal of Cancer</i> , 1993, 53, 395-400.	5.1	29
304	Dehydrogenase-dependent metabolism of alcohols in gastric mucosa of deer mice lacking hepatic alcohol dehydrogenase. <i>Biochemical Pharmacology</i> , 1993, 45, 1989-1994.	4.4	8
305	Acetone-dependent regulation of cytochromes P4502E1 and P4502B1 in rat nasal mucosa. <i>Biochemical Pharmacology</i> , 1993, 46, 1945-1951.	4.4	29
306	Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. <i>Alcohol</i> , 1993, 10, 447-452.	1.7	219

#	ARTICLE	IF	CITATIONS
307	Pulsatile blood alcohol and CYP2E1 induction during chronic alcohol infusions in rats. Alcohol, 1993, 10, 453-457.	1.7	32
308	Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics and Genomics, 1993, 3, 275-280.	5.7	53
309	Genetic polymorphism of cytochromes P450: Interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics and Genomics, 1992, 2, 264-271.	5.7	45
310	Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clinical Pharmacology and Therapeutics, 1992, 51, 12-17.	4.7	186
311	Effect of chronic hypoxia on detoxication enzymes in rat liver. Biochemical Pharmacology, 1992, 43, 2421-2426.	4.4	44
312	The microsomal monooxygenase system of regenerating liver. Biochemical Pharmacology, 1992, 43, 567-573.	4.4	11
313	Effects of Dietary Fat Composition on Activities of the Microsomal Ethanol Oxidizing System and Ethanol-Inducible Cytochrome P450 (CYP2E1) in the Liver of Rats Chronically Fed Ethanol. Basic and Clinical Pharmacology and Toxicology, 1992, 70, 347-351.	0.0	60
314	Oxidoreduction of butanol in deermice (<i>Peromyscus maniculatus</i>) lacking hepatic cytosolic alcohol dehydrogenase. FEBS Journal, 1992, 204, 353-357.	0.2	11
315	Zonation of cytochrome P450 isozyme expression and induction in rat liver. FEBS Journal, 1992, 204, 407-412.	0.2	107
316	Hormone controlled phosphorylation and degradation of CYP2B1 and CYP2E1 in isolated rat hepatocytes. Biochemical and Biophysical Research Communications, 1991, 174, 37-42.	2.1	37
317	Acetaldehyde as a substrate for ethanol-inducible cytochrome P450 (CYP2E1). Biochemical and Biophysical Research Communications, 1991, 179, 689-694.	2.1	90
318	Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols. Biochemical Pharmacology, 1991, 41, 1895-1902.	4.4	143
319	Effects of Short-Term Ethanol and Nutrition on the Hepatic Microsomal Monooxygenase System in a Model Utilizing Total Enteral Nutrition in the Rat. Alcoholism: Clinical and Experimental Research, 1991, 15, 693-699.	2.4	49
320	Hydroxylation of salicylate as an assay for hydroxyl radicals: A cautionary note. Free Radical Biology and Medicine, 1991, 10, 439-441.	2.9	259
321	Acetone-regulated synthesis and degradation of cytochrome P450E2 and cytochrome P450B1 in rat liver. FEBS Journal, 1991, 198, 383-389.	0.2	74
322	Effect of <i>in Vivo</i> Chromate, Acetone and Combined Treatment on Rat Liver <i>in Vitro</i> Microsomal Chromium(VI) Reductive Activity and on Cytochrome P450 Expression. Basic and Clinical Pharmacology and Toxicology, 1991, 68, 456-463.	0.0	7
323	Immunochemical localization and functional characterization of cytochrome P450IIE1 in rat hepatocyte foci and nodules. Carcinogenesis, 1991, 12, 2353-2356.	2.8	4
324	Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochemical and Biophysical Research Communications, 1990, 173, 331-338.	2.1	83

#	ARTICLE	IF	CITATIONS
325	Differential rates of metabolic activation and detoxication of the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by different cytochrome P450 enzymes. Carcinogenesis, 1990, 11, 489-492.	2.8	121
326	Human liver microsomal cytochrome P-450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbonyl tetrachloride reduction and NADPH oxidase activity. Biochemical Pharmacology, 1989, 38, 689-693.	4.4	73
327	Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochemical Pharmacology, 1989, 38, 1313-1319.	4.4	508
328	Protein kinase C-dependent phosphorylation of profilin is specifically stimulated by phosphatidylinositol bisphosphate (PIP2). Biochemical and Biophysical Research Communications, 1988, 150, 526-531.	2.1	49
329	Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. Biochemical and Biophysical Research Communications, 1988, 150, 436-443.	2.1	159
330	Cytochrome P-450-dependent oxidase activity and hydroxyl radical production in micellar and membranous types of reconstituted systems. Biochemical Pharmacology, 1988, 37, 1383-1389.	4.4	30
331	Centrilobular expression of ethanol-inducible cytochrome P-450 (IIE1) in rat liver. Biochemical and Biophysical Research Communications, 1988, 157, 55-60.	2.1	174
332	H2O2 activates CD11b/CD18-dependent cell adhesion. Biochemical and Biophysical Research Communications, 1988, 157, 443-449.	2.1	47
333	Phorbol-ester-induced stable changes in the regulation of DNA synthesis and intracellular pH are accompanied by altered expression of protein kinase C in the monoblastoid cell line U-937. International Journal of Cancer, 1988, 42, 284-288.	5.1	0
334	Modulation of the Substrate Specificity of Purified Human Protein Kinase C by its Activators.. Acta Chemica Scandinavica, 1987, 41b, 174-179.	0.7	6
335	Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. Biochemical and Biophysical Research Communications, 1986, 134, 1215-1222.	2.1	221
336	Hydroxylation of acetone by ethanol- and acetone-inducible cytochrome P-450 in liver microsomes and reconstituted membranes. FEBS Letters, 1986, 196, 59-64.	2.8	50
337	Metabolism of n-pentane by ethanol-inducible cytochrome P-450 in liver microsomes and reconstituted membranes. FEBS Journal, 1986, 161, 303-308.	0.2	40
338	Mechanisms of lipid peroxidation dependent upon cytochrome P-450 LM2. FEBS Journal, 1986, 158, 195-201.	0.2	42
339	Rapid effects of phorbol esters on isolated rat adipocytes. Relationship to the action of protein kinase C. FEBS Journal, 1985, 148, 407-412.	0.2	47
340	Insulin-stimulated protein synthesis in adipocytes. Enhanced rate of initiation associated with increased phosphorylation of ribosomal protein S6. FEBS Journal, 1985, 151, 97-100.	0.2	26
341	Carbon tetrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P-450. FEBS Letters, 1985, 183, 265-269.	2.8	191
342	Cytochrome P-450-dependent Fragmentation of DNA in Reconstituted Membranes. Acta Pharmacologica Et Toxicologica, 1985, 56, 69-74.	0.0	1

#	ARTICLE	IF	CITATIONS
343	Characterization of Calcium and Phospholipid Dependent Protein Kinase in Isolated Rat Adipocytes.. Acta Chemica Scandinavica, 1985, 39b, 219-226.	0.7	11
344	Mechanism of rate control of the NADPH-dependent reduction of cytochrome P-450 by lipids in reconstituted phospholipid vesicles. FEBS Journal, 1984, 144, 509-513.	0.2	41
345	Cytochrome P-450-dependent lipid peroxidation in reconstituted membrane vesicles. Biochemical Pharmacology, 1984, 33, 2521-2523.	4.4	30
346	Induction of the ethanol-inducible form of rabbit liver microsomal cytochrome P-450 by inhibitors of alcohol dehydrogenase. Biochemical and Biophysical Research Communications, 1984, 124, 375-382.	2.1	44
347	Reduction of Cytochrome P-450 LM2 by NADPH in Reconstituted Phospholipid Vesicles is Dependent on Membrane Charge. FEBS Journal, 1983, 134, 157-162.	0.2	35
348	Aniline is hydroxylated by the cytochrome P-450-dependent hydroxyl radical-mediated oxygenation mechanism. Biochemical and Biophysical Research Communications, 1982, 106, 625-631.	2.1	33
349	Interindividual Variation in Benzo(a)pyrene Metabolism and Composition of Isoenzymes of Cytochrome P-450 as Revealed by SDS-Gel Electrophoresis of Human Liver Microsomal Fractions. Acta Pharmacologica Et Toxicologica, 1982, 50, 251-260.	0.0	12
350	Cytochrome b5 as electron donor to rabbit liver cytochrome P-450LM2 in reconstituted phospholipid vesicles. Biochemical and Biophysical Research Communications, 1980, 97, 582-589.	2.1	84
351	Benzo(a)pyrene metabolism by purified forms of rabbit liver microsomal cytochrome P-450, cytochrome b5 and epoxide hydrase in reconstituted phospholipid vesicles. Biochemical and Biophysical Research Communications, 1980, 95, 431-439.	2.1	17
352	Protein amino acid analysis by an isotope ratio gas chromatography mass spectrometry computer technique. Biomedical Mass Spectrometry, 1979, 6, 317-324.	1.9	9
353	Changes in steroid hormone metabolism in rat liver microsomes following administration of 2,3,7,8-tetrachlorodibenzo-p-dioxine (TCDD). Biochemical Pharmacology, 1979, 28, 497-499.	4.4	29
354	Bioactivation or inactivation of toxic compounds?. Trends in Pharmacological Sciences, 1979, 1, 176-179.	8.7	7
355	Qualitative Alterations of Cytochrome P-450 in Mouse Liver Microsomes after Administration of Acrylamide and Methylmethacrylate. Acta Pharmacologica Et Toxicologica, 1978, 43, 299-305.	0.0	13
356	Reconstitution of the liver microsomal hydroxylase system into liposomes. FEBS Letters, 1977, 78, 72-76.	2.8	47
357	Resolution of multiple forms of phenobarbital-induced liver microsomal cytochrome P -450 by electrofocusing on granulated gels. FEBS Letters, 1977, 74, 103-106.	2.8	12
358	The Involvement of Cytochrome P-450 in Hepatic Microsomal Steroid Hydroxylation Reactions Supported by Sodium Periodate, Sodium Chlorite, and Organic Hydroperoxides. FEBS Journal, 1976, 61, 43-52.	0.2	109
359	Multiple Forms of Cytochrome P-450 in Rat-Liver Microsomes. Separation and Some Properties of Different Hydroxylases Active on Free and Sulphoconjugated Steroids. FEBS Journal, 1976, 64, 35-43.	0.2	38
360	Specific Metabolic Pathways of Steroid Sulfates in Human Liver Microsomes. Journal of Clinical Endocrinology and Metabolism, 1976, 43, 56-63.	3.6	26

#	ARTICLE	IF	CITATIONS
361	PARTIAL FEMINIZATION OF HEPATIC STEROID METABOLISM IN MALE RATS AFTER NEONATAL ADMINISTRATION OF CYPROTHERONE ACETATE. Journal of Endocrinology, 1975, 64, 267-275.	2.6	3
362	Sodium periodate, sodium chlorite, organic hydroperoxides, and H ₂ O ₂ as hydroxylating agents in steroid hydroxylation reactions catalyzed by partially purified cytochrome P-450. Biochemical and Biophysical Research Communications, 1975, 66, 209-216.	2.1	173
363	Neonatal androgenic programming of hepatic steroid metabolism in rats. The Journal of Steroid Biochemistry, 1975, 6, 643-649.	1.1	22
364	Sodium periodate, sodium chlorite, and organic hydroperoxides as hydroxylating agents in hepatic microsomal steroid hydroxylation reactions catalyzed by cytochrome P-450. FEBS Letters, 1975, 56, 161-165.	2.8	55
365	Demonstration of a cytochrome P-450-dependent steroid 15 β -hydroxylase in <i>Bacillus megaterium</i> . Biochemical and Biophysical Research Communications, 1975, 66, 1414-1423.	2.1	65
366	Sex-specific 15 β -hydroxylation of sulpho-conjugated 5 α -androstane-3 β , 17 β -diol in liver microsomes from female rats. FEBS Letters, 1973, 31, 292-296.	2.8	14
367	Liquid biopsies or therapeutic drug monitoring for <sc>CYP</sc> activity profile determination. Clinical Pharmacology and Therapeutics, 0, , .	4.7	8